Labour says the government must “come clean” on PPE procurement process after £120m face shield deals.
Category Archives: Longevity
Health24.com | ‘Trigger warnings’ may do more harm than good, study finds
- Trigger warnings at the beginning of books or films aim to prepare previously traumatised readers or viewers for potentially upsetting material
- A new study found that this precaution was not helpful to trauma survivors
- The researchers concluded that a prior warning did not lessen the impact of the disturbing material
_____________________________________________________________________________________________________________________
Trigger warnings are meant to alert trauma survivors about unsettling text or content that they might find potentially distressing.
But these words of caution at the start of films or books may provide no help at all – and might even hamper a traumatised person’s ability to grapple with deep psychological scars, a new study reports.
“We found that trigger warnings did not help trauma survivors brace themselves to face potentially upsetting content,” said lead researcher Payton Jones, a doctoral candidate in clinical psychology at Harvard University. “In some cases, they made things worse.”
Trigger warnings seem to increase the extent to which people see trauma as central to their identity, which can exacerbate cases of post-traumatic stress disorder (PTSD) in the long run, Jones and his colleagues found.
Some real soul-searching
“We found evidence that trigger warnings increased the extent to which trauma survivors saw their worst event as central to their life story,” Jones said. “Seeing trauma as central to one’s life is not a good thing.”
The study’s results are strong enough that they should provoke some real soul-searching about who’s really being helped by trigger warnings, said Guy Boysen, a professor of psychology at McKendree University in Lebanon, Illinois.
“It’s a pretty convincing argument that in the population that trigger warnings are supposed to be for, it’s not really doing much,” Boysen said. “It’s time in this research area to flip the question and ask not whether trigger warnings work, but is there any population in which they do anything?”
Previous studies on trigger warnings have had similar findings, but have been criticised because participants were from the general public and not specifically people with a history of trauma, said Boysen, an expert on the topic.
Where did trigger warnings originate?
The concept of trigger warnings evolved from work on PTSD, a condition in which reminders of trauma cause some to experience extreme emotional reactions, Boysen said.
Online discussion groups for survivors of sexual trauma came up with the idea of providing warnings in advance, so people could talk about their experiences without causing pain in others, the researchers said in background notes.
Since then, the concept has flourished. About half of all college professors told National Public Radio in a 2016 survey that they’d used trigger warnings to prepare students for potentially difficult material.
However, the practice has been adopted without any real research to confirm whether it actually helps, Jones said.
To test the effectiveness of trigger warnings, the researchers recruited 600 people who’d been exposed to a traumatic event – actual or threatened death, serious injury, or sexual violence.
Participants were split into two groups. Both read a series of literature passages that ranged from neutral to mildly distressing to markedly distressing.
The only difference was that one group received trigger warnings prior to reading distressing passages, while the other did not. Participants rated their emotions after finishing each passage, and also completed a series of psychological questionnaires at the end.
Overall, both groups appeared to react similarly to the passages. Neither seemed to be spared the emotional impact of reading the text, the researchers said.
Avoidance doesn’t help
But people given trigger warnings were more likely to express the belief that their trauma is an essential part of a survivor’s life story – something that won’t help them overcome their trauma, Jones said.
According to Boysen, “Avoidance is bad. The reason people don’t get over their phobias and traumas and fears is because they don’t allow themselves to be exposed to reminders of them or the things themselves, and that just increases their symptomology.”
Jones said the report is “one of the very first studies to test whether trigger warnings work as intended. The key takeaway for me is not that trigger warnings are ‘bad,’ but that for many years we have been implementing a policy for trauma survivors without testing whether it is actually helpful or harmful.”
Boysen suggested that trigger warnings might not work as intended because there’s simply no way to make them specific enough in a general setting.
He gave the example of a person who has been robbed at gunpoint in their own home by burglars.
“What is the trigger going to be for that? Is it going to be seeing a person who looks like that, is it going to be talking about guns, talking about robbery? It could be anything, right?” Boysen said.
Useful on an individual basis
“The triggers for things that might lead to automatic distress are so diverse, and so individualised, it’s impossible to predict in a general way what’s going to be triggering for people, because it’s 100% totally unique to that person,” Boysen added.
While generalised trigger warnings don’t appear to help, Boysen said they still could be useful on an individual basis – for example, if a student with a solid grasp of their trauma trigger lets a professor know in advance what type of content could cause distress.
“That’s a different thing, because the teacher then has more of a specific idea of what could be effective,” Boysen said.
The new study was published recently in Clinical Psychological Science.
Image credit: iStock
NEXT ON HEALTH24X
Health24.com | Tai chi could be good medicine for heart patients
- Analysis of clinical trials found that tai chi improved the mental state of almost 2 000 people
- This improvement can reduce stress, anxiety and depression among heart disease patients
- Tai chi arguably benefits practitioners’ mental state through the synergy between postures and breathing
_____________________________________________________________________________________________________________________
Tai chi might be just what doctors should order for their heart patients, new research suggests.
Many of these folks experience anxiety, stress and depression. For example, depression affects about 20% of people with heart disease or heart failure, 27% of those with high blood pressure, and 35% of stroke survivors.
Tai chi is a mind-body exercise that combines set movements with relaxation and breathing. It requires concentration on posture, relaxation and breathing.
Researchers analysed 15 clinical trials that examined how tai chi affected the mental well-being of more than 1 800 people, average age 66, who had heart disease, heart failure, high blood pressure, or had survived a stroke.
Physical and mental benefits
Overall, tai chi was associated with lower levels of mental distress, reductions in depression, and improved quality of life, including: mental health quality of life (how patients felt and their ability to go out and socialise) and physical health quality of life (walking and ability to do daily activities).
So how does tai chi benefit your mental state? “I think it’s the synergy between postures and breathing. During tai chi, you have good body posture, and research has shown that this enhances mood. We also know that holding your breath can cause stress and anxiety,” explained study author Ruth Taylor-Piliae, from the University of Arizona.
However, the study found no statistically significant association between tai chi and reduced anxiety, and tai chi did not have a noticeable impact on the well-being of stroke survivors. The findings were published on 8 June in the European Journal of Cardiovascular Nursing.
“This is because there were very few studies on psychological well-being or quality of life variables in this group. There is a lot of research on tai chi in stroke survivors, but nearly all of them looked at physical function such as balance and gait,” Taylor-Piliae said in a journal news release.
Further research is needed to learn how tai chi can improve mental health, she noted.
“If you’ve had a heart attack or stroke, or are affected by another heart condition, I would strongly recommend adding tai chi to your recovery and rehabilitation,” Taylor-Piliae said. “There are physical benefits like improved balance, and it’s good for mental health, too.”
Image credit: iStock
Coronavirus: Dementia patients ‘deteriorating’ without family visits
Relatives fear residents with dementia are deteriorating as coronavirus restrictions limit visitors.
Community initiative increases teenage use of effective contraception
A new study published in the American Journal of Obstetrics & Gynecology shows that a University of Rochester Medical Center (URMC) community outreach initiative has helped adolescents in Rochester adopt long-acting reversible contraception (LARC) at a rate far higher than the U.S. overall.
The study, “Impact of the Rochester LARC Initiative on Adolescents’ Utilization of Long-Acting Reversible Contraception,” used Youth Risk Behavior Surveillance System data from the years 2013, 2015, and 2017 for Rochester, New York City, New York State, and the U.S. overall. These years cover the time before and after the Initiative began in 2014.
The study found that usage of LARC among sexually active high school females in Rochester increased from 4 to 24 percent from 2013-2017, compared to an increase from 2.7 to 5.3 percent in New York City, 1.5 to 4.8 percent in New York State, and 1.8 to 5.3 percent in the U.S. overall.
The Greater Rochester LARC Initiative was started six years ago by the Hoekelman Center for Health Beyond Medicine, a unit of the URMC Department of Pediatrics that connects doctors with non-profits to benefit kids and adults by making communities healthier places to live. Primarily funded by the Greater Rochester Health Foundation, the Initiative aims to increase access to highly effective methods of birth control, including intrauterine devices and contraceptive implants (LARCs) for adolescents in Rochester.
Andrew Aligne, M.D., M.P.H., director of the Hoekelman Center, and his team have led the community effort to promote LARC by conducting outreach to local organizations that work with youth. They employ a simple “lunch-and-learn” approach to disseminate accurate information that forms the backbone of the Hoekelman Center’s advocacy work.
“An interesting aspect of the LARC project is that we talk to adults, not to teens. We work with our community partners to teach adults about birth control. This way, they can help teens to make well-informed choices about preventing unintended pregnancy,” says Jessica VanScott, M.P.H., the LARC Initiative’s health project coordinator.
Through their research with area teens, the LARC project team found that many were interested in learning about birth control, and that they often asked their most trusted peers and adults for advice.
“If teens are learning outside the medical setting from trusted youths and adults, then how do we increase the likelihood that anyone they talk to will share accurate information? We thought it could help if we gave resources with useful information to adults who work with teens in the community,” said Aligne, associate professor of Pediatrics at URMC.
So far, the team has presented to more than 2,700 adults in health care settings, as well as those in community settings such as staff of after-school programs. The talks provide information about the safety, efficacy, and availability of LARC, with the goal of improving knowledge and access at the community level.
This approach is different from previous attempts to disseminate information about LARC. Typically, past outreach efforts have focused on targeting primary care providers or utilizing advertising resources to raise awareness. The Hoekelman Center’s community-based approach achieved strong results because few of these community organizations had ground-level information available about LARC, according to Aligne.
“Almost nobody knew that the LARC program was free and covered by Medicaid,” said Aligne. 26 states offer reimbursement for LARC under the Medicaid Family-Planning Benefit — included as part of the Medicaid expansion in the Affordable Care Act (ACA) — and Aligne believes these states could scale-up the Hoekelman Center’s model to raise awareness as well.
Studies have shown that unintended teen pregnancy can lead to a number of critical health and social problems for young parents and their children: low birth weight, unemployment, school failure, and many other serious issues. Because of these risks, the Centers for Disease Control and Prevention (CDC) has declared teen pregnancy a national public health priority, and the CDC — along with the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists — recommends LARC as a safe and highly effective method of pregnancy prevention for adolescents seeking contraception.
“LARCs are more effective than pills, patches, and other contraceptives because they remain in place all the time,” said Katherine Greenberg, M.D., an adolescent medicine specialist at UR Medicine’s Golisano Children’s Hospital. “Today’s LARCs are safe, effective, invisible, and can be easily removed with no lingering effects when you decide to become pregnant.” LARC methods protect against pregnancy for up to three to 12 years, can be removed at any time, and are 40 times more effective for teens than the traditional birth control pill.
The Hoekelman Center’s efforts are bolstered by an extensive network of local agencies, including the Initiative’s core partners: the Metro Council for Teen Potential, Healthy Baby Network, Highland Family Planning, and Planned Parenthood of Central and Western New York.
“As we strive to fulfill our mission to pursue and invest in solutions that build a healthier region where all people can thrive, we are proud to support the LARC Initiative at URMC, and celebrate its successes,” said Matthew Kuhlenbeck, president and CEO of the Greater Rochester Health Foundation.
“The LARC project team takes a proactive, practical approach in its efforts to help reduce teen pregnancy by sharing information and increasing awareness of options, and we are especially grateful for the collaboration among URMC and community partners who are working together to address this challenge.”
LARC services have continued during COVID-19, and access expanded at an increasing number of primary care practices serving teens and young adults throughout the Finger Lakes region during the last year, thanks to Accountable Health Partners (AHP), URMC’s clinically integrated network of hospitals and physicians. In partnership with the Hoekelman Center team, and funded by a grant from the Finger Lakes Performing Provider System (FLPPS), AHP has promoted training in both reproductive counseling and LARC placement for primary care providers in order to further reduce access barriers for patients.
“The LARC Initiative demonstrates true collaboration between health care and community and is a significant population health success for our region,” said Laura Jean Shipley, M.D., professor of clinical pediatrics, vice chair for Population and Behavioral Health at URMC and associate medical director at AHP.
A complex gene program initiates brain changes in response to cocaine
The lab of Jeremy Day, Ph.D., at the University of Alabama at Birmingham, has used single-nucleus RNA sequencing approaches to compare transcriptional responses to acute cocaine in 16 unique cell populations from a portion of the brain called the nucleus accumbens, or NAc. This molecular atlas is “a previously unachieved level of cellular resolution for cocaine-mediated gene regulation in this region,” said Day, an associate professor in the UAB Department of Neurobiology.
The atlas was just the beginning of a major study, published in the journal Science Advances, that used multiple cutting-edge technologies to describe a dopamine-induced gene expression signature that regulates the brain’s response to cocaine.
“These results mark a substantial advance in our understanding of the neurobiological processes that control drug-related adaptations,” Day said. “They also reveal new information about how transcriptional mechanisms regulate activity-dependent processes within the central nervous system.”
The approaches used in this study, Day says, may also help dissect the role of similar gene programs that mediate other types of behavior, memory formation or neuropsychiatric disorders.
The NAc is deeply involved in drug addiction, and detailed understanding of how drugs alter its neural circuitry to initiate addictive behavior can suggest new therapeutic interventions. The NAc is a central integrator of the brain’s reward circuit, and all addictive drugs acutely raise the level of the neurotransmitter dopamine in the NAc. Dopamine signaling during repeated drug use leads to widespread changes in gene expression, initiating alterations in neural synaptic circuitry and changes in behavior associated with drug addiction.
Previous studies of changes in NAc gene expression were only able to look at bulk tissue — a mix of many different cell types. When the Day lab looked at single cell changes by RNA-sequencing 15,631 individual rat NAc nuclei, they found a surprise. Only a small fraction of neurons in the NAc were transcriptionally responsive to cocaine administration — mainly a specific subcluster of medium spiny neurons that express the Drd1 dopamine receptor.
The researchers next comprehensively defined the core gene structure that is activated when dopamine is added to a striatal neuron culture system. Similar to the responses in the rat NAc after cocaine administration, transcriptional activation predominantly occurred in Drd1-receptor-medium spiny neurons. Day and colleagues identified a core set of around 100 genes altered by dopamine, which also correlated with key genes activated in the NAc of rats given cocaine.
It has been hypothesized that gene expression programs in the brain work in concert to produce downstream effects on neuronal function and behavior. However, until recently researchers have lacked a way to test key gene expression programs, which requires inducing multiple genes at the same time.
Day and colleagues engineered a multiplexed CRISPR guide-RNA array to target 16 of the top candidate genes altered by dopamine. When paired with a neuron-optimized CRISPR/dead-Cas9 activation system, they were able to simultaneously upregulate the 16 genes in neuronal cultures or in the NAc of live rats. They then explored the transcriptional, physiological and behavioral consequences.
In primary neuronal culture, induction of this gene signature produced large-scale transcriptional changes that were enriched for genes involved in synaptic plasticity, neuronal morphogenesis and ion channel function. This program also significantly increased neuron burst firing frequency. In live rats, induction of the gene signature produced sensitization to repeated cocaine administration. These changes seen in the neuronal culture and live rats are similar to the neuronal and behavioral changes initiated by drugs of abuse.
Day says his group’s study is the first proof-of-principle evidence that CRISPR activation can be used for simultaneous and selective regulation of a gene expression signature in vivo.
“Critically,” Day said, “these results represent the first demonstration — to our knowledge — of multiplexed gene regulation in any neuropsychiatric model, providing a roadmap for future studies to investigate the relationship between altered gene programs and neuronal disease states.
“While the present work provides insight into how cellular diversity contributes to transcriptional responses after an initial cocaine experience,” Day said, “repeated exposure to drugs of abuse promotes neurophysiological adaptations that are thought to drive compulsive drug-seeking long after cessation of use. Hence, it will be critical for future studies to expand on this work by examining the transcriptional consequence of repeated or self-administered drug use at the single-cell level, as well as understanding how these changes are maintained within different cell populations over longer periods of time and as a result of volitional drug experience.”
Story Source:
Materials provided by University of Alabama at Birmingham. Original written by Jeff Hansen. Note: Content may be edited for style and length.
New study supports remdesivir as COVID-19 treatment
The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better.
This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.
These preclinical findings help explain the clinical effect the drug has had in treating COVID-19 patients. Remdesivir has been given to patients hospitalized with COVID-19 on a compassionate use basis since late January and through clinical trials since February.
In April, a preliminary report from the multicenter Adaptive COVID-19 Treatment Trial (which included VUMC) suggested that patients who received the drug recovered more quickly.
“All of the results with remdesivir have been very encouraging, even more so than we would have hoped, but it is still investigational, so it was important to directly demonstrate its activity against SARS-CoV-2 in the lab and in an animal model of disease,” said VUMC’s Andrea Pruijssers, PhD.
Pruijssers, research assistant professor of Pediatrics at VUMC and lead antiviral scientist in the laboratory of Mark Denison, MD, is the paper’s co-corresponding author with Timothy Sheahan, PhD, assistant professor of Epidemiology at UNC-Chapel Hill.
Denison, the E.C. Stahlman Professor of Pediatrics at VUMC, directs the Division of Pediatric Infectious Diseases. He and Ralph Baric, PhD, the William R. Kenan, Jr. Distinguished Professor of Epidemiology at UNC-Chapel Hill, and colleagues have been studying remdesivir since 2014.
They were the first to perform detailed studies to demonstrate that the drug, which was developed by Gilead Sciences to combat hepatitis C and respiratory syncytial virus, and later the Ebola virus, also showed broad and highly potent activity against coronaviruses in laboratory tests.
The current findings, reported this week in the journal Cell Reports, provide “the first rigorous demonstration of potent inhibition of SARS-CoV-2 in continuous and primary human lung cultures.” The study is also the first to suggest that remdesivir can block the virus in a mouse model.
Ongoing clinical trials will determine precisely how much it benefits patients in different stages of COVID-19 disease.
Meanwhile in the laboratory, Pruijssers said, “We also are focusing on how to use remdesivir and other drugs in combinations to increase their effectiveness during COVID-19 and to be able to treat at different times of infection.”
COVID-19, which to date has infected more then 12 million people and killed nearly 600,000 worldwide, is at least the third instance since 2003 in which a coronavirus originally transmitted from bats has caused serious illness in humans.
Thus there is an urgent need to identify and evaluate broadly efficacious and robust therapies that can limit and prevent coronavirus infections. “Broad-spectrum antiviral drugs, antibodies, and vaccines are needed to combat the current pandemic and those that will emerge in the future,” the researchers said.
In addition to SARS-CoV-2, studies in the Denison and Baric labs have shown that remdesivir is effective against a vast array of coronaviruses, including other bat viruses that could emerge in the future in humans.
“We hope that will never happen, but just as we were working to characterize remdesivir over the past six years to be ready for a virus like SARS-CoV-2, we are working and investing now to prepare for any future coronavirus,” Denison said. “We want remdesivir and other drugs to be useful both now and in the future.”
Others VUMC co-authors were Amelia George, MS, Maria Agostini, PhD, Laura Stevens, MS, James Chappell, MD, PhD, Xiaotao Lu, MS, and Tia Hughes, MS.
The study was supported by National Institutes of Health grants AI142759, AI132178 and AI132178-03S1, AI081197 and AI007151, the Dolly Parton COVID-19 Research Fund and the Elizabeth B. Lamb Center for Pediatric Research at Vanderbilt.
Health24.com | Loneliness may make quitting smoking even tougher
- Lonely people may be more likely to smoke
- Smoking has been identified as a risk factor for poor mental health as nicotine interferes with neurotransmitters
- Factoring loneliness in as a cause may help smoking cessation services to get people to quit
Being lonely may make it harder to quit smoking, a new British study suggests.
Using genetic and survey data from hundreds of thousands of people, researchers found that loneliness makes it more likely that someone will smoke. This type of analysis is called Mendelian randomisation.
“This method has never been applied to this question before and so the results are novel, but also tentative,” said co-lead author Robyn Wootton, a senior research associate at the University of Bristol in the United Kingdom.
“We found evidence to suggest that loneliness leads to increased smoking, with people more likely to start smoking, to smoke more cigarettes and to be less likely to quit,” Wootton said in a university news release.
Risk factor for poor mental health
These data mesh with an observation that during the coronavirus pandemic, more British people are smoking.
Senior study author Jorien Treur said, “Our finding that smoking may also lead to more loneliness is tentative, but it is in line with other recent studies that identified smoking as a risk factor for poor mental health. A potential mechanism for this relationship is that nicotine from cigarette smoke interferes with neurotransmitters such as dopamine in the brain.” Treur is a visiting research associate from Amsterdam UMC.
The researchers also looked for a connection between loneliness and drinking but found none.
Still, if loneliness causes people to smoke, it is important to alert smoking cessation services so they can add this factor as they help people to quit, the study authors said.
The report was published on 16 June in the journal Addiction.
Image credit: iStock
Coronavirus: Data shows cases in England falling
Two reports charting coronavirus show cases in England falling – with Leicester also seeing a fall.
Health24.com | Pill might prevent life-threatening allergic reactions
- Anaphylaxis is a potentially deadly allergic reaction to normally innocent substances
- A group of medications called BTK inhibitors can slow the anaphylactic response
- Test have shown promising results, but the pills are very expensive
Pills used to treat blood cancers may potentially prevent life-threatening allergic reactions, early research hints.
That could spell good news for people with severe food and drug allergies.
In lab experiments, researchers found that a group of medications – called BTK inhibitors – can put the brakes on the process that triggers life-threatening allergic reactions known as anaphylaxis.
Anaphylaxis arises from a haywire immune response to a normally benign substance – with certain foods, insect stings and medications common triggers. The reaction occurs quickly after exposure, causing symptoms like breathlessness, rapid hear rate and dangerous drops in blood pressure.
Fear of anaphylaxis
There is no magic bullet to prevent anaphylaxis – a condition that affects at least one in 50 Americans, and possibly up to one in 20, according to the Asthma and Allergy Foundation of America.
But researchers hope the new work might pave the way to a pill that can offer broad protection.
That would be “life-changing” for people who live in fear of anaphylaxis, according to senior researcher Dr Bruce Bochner.
Right now, he said, those people largely depend on avoiding their allergy trigger, which can be difficult. Otherwise, there are some options for warding off certain severe reactions, said Bochner, a professor of medicine at Northwestern University Feinberg School of Medicine in Chicago.
Allergy shots can effectively prevent anaphylaxis from insect stings, for example. And a pill called Palforzia has recently been approved by the US Food and Drug Administration to help prevent severe reactions in children with known peanut allergy.
But if BTK inhibitors pan out, they might offer protection that is not dependent on the type of allergy, Bochner said. BTK stands for Bruton’s tyrosine kinase, and it’s an enzyme within cells that helps set off allergic reactions; blocking it, in theory, could thwart all kinds of allergies.
Reduction in allergic responses
The new findings were published on 2 June in the Journal of Clinical Investigation. They’re based on experiments in the test tube and in lab mice.
Bochner’s team found that three different BTK inhibitors can block allergic responses in human mast cells, which release histamine and other substances that fuel allergy symptoms. And one drug was able to block allergic reactions in lab mice that had human mast cells transplanted into their bodies.
The research was partially funded by Acerta Pharma, which makes the BTK inhibitor acalabrutinib (Calquence).
The results back up two earlier, small studies in humans, by Bochner’s co-researchers Drs Jennifer Regan and Melanie Dispenza.
In one, cancer patients who were on the BTK inhibitor ibrutinib (Imbruvica) had a reduction in their usual allergic responses to pollen and cat dander. In the other, people with food allergies who were given ibrutinib for a few days showed less reactivity on standard allergy skin tests.
However, such test results do not necessarily translate into effectiveness against real-world allergic reactions, according to Dr Thomas Casale. He is chairman of the clinical network steering committee for the non-profit Food Allergy Research and Education.
Casale, who was not involved in the study, called the results “promising”, but said critical questions remain.
Safety questions to be answered
One issue, he said, is that BTK is involved in not only allergic reactions, but normal immune defences. “Whereas blocking this enzyme can be effective in treating certain types of cancers,” Casale said, “there’s a concern that patients would have defects in their immune system that could predispose them towards adverse consequences.”
Some of the known side effects of the drugs, as used for cancer, include pneumonia and a drop in certain white blood cells, Casale pointed out.
Bochner agreed that safety questions have to be answered – particularly regarding children.
“None of these drugs are approved for children,” he said. “With any drug for food allergy, you’d need it to be safe and effective in kids.”
Cost a big issue
And when it comes to food allergies, Casale said, a preventive drug would have to be taken chronically, since exposures are often accidental.
Short-term treatment, he added, would only be helpful for managing high-risk situations – if, for example, someone with a penicillin allergy needed to take that drug.
The notion of long-term treatment brings up another issue: cost. Casale and Bochner said the drugs’ current price tags make them prohibitively expensive. They are in the range of $15 000 (R260 000) for a month’s supply, according to Bochner.
So for now, he said, the findings offer more evidence that the BTK “pathway” is important in allergic reactions, and worth further study.
Image credit: iStock
NEXT ON HEALTH24X








